SanBio and Teijin to Terminate Licensing Agreement regarding SB623 for Stroke Treatment

Tokyo, Japan, February 14, 2018 --(Healthcare Sales & Marketing Network)-- SanBio, Inc. and Teijin Limited jointly announced today that they would terminate the exclusive licensing agreement signed in 2009 regarding the development and marketing of SB623 f... Biopharmaceuticals, Neurology, Licensing Teijin Limited, SanBio Inc, stroke

Source: HSMN NewsFeed - February 14, 2018 Category: Pharmaceuticals Source Type: news